FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as …
Dec 3, 2021 · Non-Small Cell Lung Cancer. KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with …
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant …
Oct 28, 2024 · RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-009, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA ® (pembrolizumab), Merck ...
FDA approves pembrolizumab with chemotherapy for …
On September 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced...
FDA approves neoadjuvant/ adjuvant pembrolizumab for …
On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of...
FDA approves pembrolizumab for adjuvant treatment
On November 17, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high...
Health Canada Approves KEYTRUDA - Merck Canada
Apr 19, 2024 · The trial enrolled 1579 patients who had not previously received systemic therapy for metastatic disease and were randomized 1:1 to receive pembrolizumab (200 mg every three weeks) in combination with fluoropyrimidine- and platinum-containing chemotherapy (n=790), or placebo in combination with chemotherapy (n=789).
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval …
RAHWAY, N.J., October 24, 2024 -- (BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved two new...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
May 5, 2021 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
Nov 16, 2023 · FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. Save. November 16, 2023 5:40 pm ET.
Health Canada Approves KEYTRUDA® (pembrolizumab) in ... - Merck …
Nov 24, 2021 · KIRKLAND, QC – November 23, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Health Canada has granted conditional approval for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy for the treatment of locally …